GNL2: A Potential Drug Target and Biomarker for Nucleolar Guanosine 5'-Triphosphate Binding Protein Autoantigen

Target Name: GNL2

NCBI ID: G29889

GNL2

GNL2: A Potential Drug Target and Biomarker for Nucleolar Guanosine 5'-Triphosphate Binding Protein Autoantigen

Introduction

Nucleolar Guanosine 5'-Triphosphate (GTP) binding proteins (GNPs) are a family of proteins that play a crucial role in regulating various cellular processes, including DNA replication, transcription, and translation. GNPs are composed of three subunits: GNP1, GNP2, and GNP3. GNP1 and GNP3 are predominantly expressed in the nucleolus, while GNP2 is expressed in the cytoplasm. The GNP family has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

GNL2, a novel nucleolar GTP binding protein autoantigen, has been identified as a potential drug target and biomarker. GNL2 is a 21-kDa protein that is expressed in various tissues, including muscle, liver, and heart. It is composed of three subunits, including a 16-kDa N-terminal subunit, a 96-kDa middle subunit, and a 32-kDa C-terminal subunit.

Expression and Localization of GNL2 in Tissues

GNL2 is expressed in various tissues, including muscle, liver, and heart. In muscle, GNL2 is expressed in the sarcolemma, the outer membrane of muscle cells, and in the intermyofibrillary space (IMS). In liver, GNL2 is expressed in the hepatocellular carcinoma (HCC) tissues and in the alanine aminotransferase (ALT) positive tissues. In heart, GNL2 is expressed in the myocardium, the heart muscle tissue.

Function of GNL2

GNL2 is a nucleolar GTP binding protein that plays a crucial role in regulating various cellular processes, including DNA replication, transcription, and translation. GNL2 has been shown to interact with various nucleolar proteins, including GNP1, GNP3, and APF1 (6 ). GNL2 has been shown to regulate the activity of the transcription factor, p53, by binding to its N-terminus.

Additionally, GNL2 has been shown to play a role in the regulation of cellular apoptosis. GNL2 has been shown to induce apoptosis in various cell types, including cancer cells (8) and myocardial infarction.

Potential Therapeutic Applications of GNL2

GNL2 has been identified as a potential drug target and biomarker for various diseases. One potential therapeutic application of GNL2 is the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. GNL2 has been shown to interact with the neurotransmitter, 尾-amyloid, and has been shown to play a role in the regulation of 尾-amyloid toxicity.

Another therapeutic potential application of GNL2 is the treatment of cancer. GNL2 has been shown to interact with various oncogenic factors and has been shown to play a role in the regulation of cancer cell growth and survival.

Biomarker Analysis

To determine the potential biomarker potential of GNL2, several studies have been conducted. One study reported that GNL2 was significantly overexpressed in the primary cultures of human breast cancer samples, and its expression was correlated with the cancer diagnosis and prognosis.

Another study reported that GNL2 was overexpressed in the primary cultures of human colorectal cancer samples and its expression was correlated with the cancer diagnosis and prognosis.

In addition, a study reported that GNL2 was overexpressed in the primary cultures of

Protein Name: G Protein Nucleolar 2

Functions: GTPase that associates with pre-60S ribosomal subunits in the nucleolus and is required for their nuclear export and maturation (PubMed:32669547). May promote cell proliferation possibly by increasing p53/TP53 protein levels, and consequently those of its downstream product CDKN1A/p21, and decreasing RPL23A protein levels (PubMed:26203195)

The "GNL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets